课题基金 / 基金详情

METABOLISM OF LP(A) IN HUMANS

METABOLISM OF LP(A) IN HUMANS
LP(A) 在人体中的代谢
批准号:
3858032
负责人:
D J RADER
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

D J RADER的其他基金

相似基金

相关文献

中文摘要
翻译
Lp(a)是一种脂蛋白,与患心脏病的风险高度相关
英文摘要
Lp(a) is a lipoprotein which is highly associated with risk of premature atherosclerotic cardiovascular disease. The protein which identifies this unique lipoprotein is apo(a), which has high homology with plasminogen. Apo(a) is polymorphic, with many different sizes of this protein in the population. This size polymorphism is genetically determined, and in turn, is a major determinant of the plasma level of Lp(a). However, other factors also strongly influence Lp(a) levels but are very poorly understood. The in vivo metabolism of radiolabeled Lp(a) was determined in groups of subjects with the same apo(a) isoform but widely different levels of Lp(a). The catabolic rates of Lp(a) were not significantly different among study subjects, whereas Lp(a) production rates were very different. Therefore, a major factor affecting levels of Lp(a) apart from apo(a) isoform appears to be the rate of production of the Lp(a) lipoprotein. This has important implications for the understanding of Lp(a) metabolism and the clinical approach to patients with high levels of Lp(a) and premature coronary heart disease. These studies included subjects of age 20 to 38 years. 42% of the subjects were women. The studies included one African-American and one Asian subjects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
APOLIPOPROTEIN METABOLISM IN CETP DEFICIENCY AND HYPERALPHALIPOPROTEINEMIA
APOLIPOPROTEIN METABOLISM IN CETP DEFICIENCY AND HYPERALPHALIPOPROTEINEMIA
HDL METABOLISM IN HYPOALPHALIPOPROTEINEMIA
APOLIPOPROTEIN METABOLISM IN CETP DEFICIENCY AND HYPERALPHALIPOPROTEINEMIA
海外基金